<unk>  has also been used to treat Sézary syndrome, another type of lymphoma closely related to CTCL. A recent study suggested that<unk>  also possesses some activity against recurrent glioblastoma multiforme, resulting in a median overall survival of 5.7 months (compared to 4–4.4 months in earlier studies). Further brain tumor trials are planned in which<unk>  will be combined with other drugs. Including<unk>  in treatment of advanced non-small-cell lung carcinoma (NSCLC) showed improved response rates and increased median progression free survival and overall survival. It has given encouraging results in a phase II trial for myelodysplastic syndromes in combination with idarubicin and cytarabine.
Vorinostat
Febuxostat
Carfilzomib
Sunitinib
Ixazomib
Tazarotene
Pomalidomide
Gilteritinib